Faron Pharmaceuticals Oy (LSE:FARN), the Finnish clinical-stage biotechnology company, is preparing for one of the most important stages of its development programme. The company is getting ready to start a randomised Phase 2b trial of its lead drug, bexmarilimab, in a form of blood cancer. Its half-year report, published on 26 August 2026, showed a much firmer cash position after a rights issue earlier in the year. The company said the new trial was planned to begin in the second half of 2026.

What the Company Does

Faron is based in Finland and its shares are traded on AIM in London as well as in Helsinki. Its main asset is bexmarilimab, an antibody aimed at the Clever-1 receptor on immune cells, which the company is developing as an immunotherapy. Its most advanced work is in higher-risk myelodysplastic syndrome (HR-MDS), a group of bone marrow cancers, where the drug is tested in combination with the standard therapy azacitidine.

Latest Developments

The planned BEXERA study is a placebo-controlled, randomised Phase 2b trial in previously untreated HR-MDS. Faron said it would enrol 90 participants at up to 35 sites in the United States, Europe and the UK, with Parexel acting as the contract research organisation. The trial is designed to select a dose for Phase 3 and to test efficacy and safety alongside azacitidine. It uses complete remission as its endpoint, which the company said was intended to support future registration filings.

Data from the earlier BEXMAB Phase 1/2 study, presented at the European Hematology Association congress in 2026, showed a median complete remission duration of 16.1 months in treatment-naive HR-MDS patients. A first overall survival data cut, reported on 27 July 2026, found that after a median follow-up of 14.9 months only the subgroup with biallelic TP53 mutations had reached median survival, at 8.8 months. Faron said this was consistent with historical data. Several investigator-initiated trials are also running in other cancers, including sarcoma, melanoma, lung cancer and acute myeloid leukaemia.

Financial Picture

Faron's rights issue raised gross proceeds of about EUR 40.1 million, with final results announced on 9 April 2026. As a result, cash and cash equivalents stood at EUR 32.0 million at 30 June 2026, against EUR 12.3 million at the end of 2025. The operating loss for the first half was EUR 11.1 million, compared with EUR 11.8 million a year earlier. The net loss narrowed to EUR 8.5 million from EUR 19.3 million. Borrowings were about EUR 17.8 million at the period end. As a loss-making drug developer, Faron does not pay a dividend.

Chief executive Juho Jalkanen said Faron was "better positioned than ever" to advance bexmarilimab to its next milestones.

Sector and index Context

Faron is one of several life sciences companies in the FTSE AIM All Share Index whose valuations depend largely on clinical results rather than current earnings. The wider biotech sector has seen investors favour companies with clear late-stage data and adequate funding, and the rights issue has eased near-term financing pressure.

Key Risks

Clinical trials can Fail or be delayed, and BEXERA has not yet produced results. Faron still carries significant borrowings and has historically needed repeated fundraising, which has diluted shareholders; its share count rose to about 202.9 million after the rights issue. Regulators may take a different view of the trial endpoints than the company expects.

What to Watch Next

Key points to follow include the first patient dosed in BEXERA, further survival data from BEXMAB and progress in the investigator-led studies. The company has also said it plans a dedicated Phase 2 trial in acute myeloid leukaemia.